Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|November 28, 2006
1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitorsMark J Mulvihill, Qun-Sheng Ji, Doug Werner, et al.
Molecular Cancer Therapeutics|September 4, 2025
In Vivo Tumor Growth Control by General Control Nonderepressible 2-Targeting Agents Results from Kinase ActivationFeven Tameire, Paulina Wojnarowicz, Crissy Dudgeon, et al.
Molecular Cancer Therapeutics|August 20, 2025
In Vivo Tumor Growth Control by General Control Nonderepressible 2 Targeting Agents Results from Kinase ActivationFeven Tameire, Paulina Wojnarowicz, Crissy Dudgeon, et al.
Bioorganic & Medicinal Chemistry|November 7, 2007
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitorsMark J Mulvihill, Qun-Sheng Ji, Heather R Coate, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2006
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agentMark J Mulvihill, Julie L C Kan, Andrew Cooke, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IRMeizhong Jin, Prafulla C Gokhale, Andy Cooke, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2Andrew P Crew, Shripad V Bhagwat, Hanqing Dong, et al.
ACS Medicinal Chemistry Letters|April 16, 2021
Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 InhibitorsJohan J N Veerman, Yorik B Bruseker, Eddy Damen, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 2013
Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1Keith R Hornberger, Dan M Berger, Andrew P Crew, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2021
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitorsVeronica Calvo, David Surguladze, An-Hu Li, et al.
Pageof 4